Pilot Study Of The Effects Of Resveratrol On Endothelial Function In Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria: 1. Male and Female subjects. 2. Age over 21 years old. 3. Body mass index greater than or equal to 25 and less than 35 kg/m2 4. Clinically stable Type 2 diabetes mellitus. 5. Willing to give written informed consent and able to understand, to participate in and to comply with the study requirements. 6. Willing to refrain from consumption of red wine, grape juice, and grape products beginning two weeks before and continuing throughout the entire study period. Exclusion Criteria: 1. Women who lactating or pregnant. All women with childbearing potential will undergo a urine pregnancy test at each visit to exclude pregnancy. 2. Treatment with an investigational product within the last 30 days. 3. Clinically evident major illness of other organ systems, including end-stage cancer, renal failure, or other conditions that in the opinion of the principal investigator make a clinical study inappropriate. 4. Liver transaminase levels greater than 3X the upper limit of normal. 5. History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study. 6. Vitamin supplements exceeding two times the recommending daily allowance (RDA) within the last 30 days prior to screening. 7. Resveratrol, green tea and isoflavone supplements within the last 30 days prior to screening. 8. Subjects who practice a vegetarian or vegan diet 9. Subjects taking budesonide, buspirone, eplerenone, eletriptan, felodipine, midazolam, saquinavir, sildenafil, triazolam, vardenafil, alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, irinotecan, pimozide, quinidine, sirolimus, tacrolimus, terfenadine, or warfarin.